Geron Corporation (GERN)

NASDAQ: GERN · IEX Real-Time Price · USD
2.19
-0.04 (-2.02%)
Mar 30, 2023, 11:03 AM EDT - Market open
-2.02%
Market Cap 1.11B
Revenue (ttm) 596,000
Net Income (ttm) -141.90M
Shares Out 508.72M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 868,651
Open 2.25
Previous Close 2.23
Day's Range 2.18 - 2.26
52-Week Range 1.18 - 3.84
Beta 0.78
Analysts Buy
Price Target 5.10 (+133.41%)
Earnings Date May 8, 2023

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 1996
Employees 98
Stock Exchange NASDAQ
Ticker Symbol GERN
Full Company Profile

Financial Performance

In 2022, Geron's revenue was $596,000, a decrease of -57.21% compared to the previous year's $1.39 million. Losses were -$141.90 million, 22.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 133.41% from the latest price.

Price Target
$5.1
(133.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock a...

1 week ago - Business Wire

Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematolog...

1 week ago - Business Wire

Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 fina...

2 weeks ago - Business Wire

Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Execu...

2 months ago - Business Wire

Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today highlighted multiple additions to its senior commercial leadership team...

2 months ago - Business Wire

Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of co...

2 months ago - Business Wire

Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consis...

2 months ago - Business Wire

Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes

Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.

2 months ago - Zacks Investment Research

Geron Corporation Announces Proposed Public Offering of Common Stock

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of i...

3 months ago - Business Wire

Why Is Geron (GERN) Stock Soaring 50% Today?

Though the major indices posted a strong recovery effort on Wednesday, late-stage clinical biopharmaceutical firm Geron (NASDAQ: GERN) soared above most public players. Following positive top-line re...

3 months ago - InvestorPlace

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical tr...

3 months ago - Business Wire

Geron Announces Conference Call for Top-Line Results from IMerge Phase 3

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imete...

3 months ago - Business Wire

Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced results from an oral presentation at the 64th American Societ...

3 months ago - Business Wire

Geron to Participate in Stifel 2022 Healthcare Conference

FOSTER CITY, Calif.

5 months ago - Business Wire

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Is Geron (GERN) Outperforming Other Medical Stocks This Year?

Here is how Geron (GERN) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

7 Top-Rated Biotech Stocks to Buy for Q4

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

6 months ago - InvestorPlace

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of...

7 months ago - Business Wire

Geron to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignanci...

7 months ago - Business Wire

Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 s...

7 months ago - Business Wire

Geron Corporation Reports Second Quarter 2022 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematolog...

8 months ago - Business Wire